Clin Exp Otorhinolaryngol.  2011 Dec;4(4):193-198.

Association of the Oncostatin M Receptor Gene Polymorphisms with Papillary Thyroid Cancer in the Korean Population

• Hong IK
• Eun YG
• Chung DH
• Kwon KH
• Kim DY

Abstract

OBJECTIVES
To investigate the association between papillary thyroid cancer (PTC) and single nucleotide polymorphisms (SNPs) of oncostatin M receptor (OSMR) in the Korean population.
METHODS
Retrospective case-control study was done. Eighty-five patients with PTC and 287 controls were studied. One missense SNP (rs2278329, Asp553Asn) and one promoter SNP (rs2292016, -100 G/T) of the OSMR gene were genotyped by direct sequencing. Genetic data were analyzed using the SNPStats, Helixtree, and SNPAnalyzer Pro. PTC patients were dichotomized and compared with respect to the clinicopathologic characteristics.
RESULTS
There was no association between genotypes and allele frequencies of OSMR SNPs (rs2278329 and rs2292016) and PTC susceptibility. SNP rs2278329 was significantly associated with tumor size (dominant model; P=0.028; odds ratio [OR], 2.71; 95% confidence interval [CI], 1.12 to 6.57). The A allele was higher in sizes large than 1 cm (32.5% vs. 16.7%; P=0.018; OR, 2.41; 95% CI, 1.17 to 4.98). Regarding the number of tumors, we found no significant association with genotype, however, the A allele was higher in patients with multifocaltiy (33.3% vs. 19.1%; P=0.040; OR, 2.12; 95% CI, 1.03 to 4.34).
CONCLUSION
The results suggest that OSMR polymorphism rs2278329 is associated with clinicopathologic characteristics of the tumor growth and multifocality development.

Keyword

Papillary thyroid cancer; Oncostatin M receptor; Single nucleotide polymorphism; Clinicopathologic status

MeSH Terms

Alleles
Case-Control Studies
Factor IX
Gene Frequency
Genotype
Humans
Odds Ratio
Oncostatin M
Polymorphism, Single Nucleotide
Receptors, Oncostatin M
Retrospective Studies
Thyroid Gland
Thyroid Neoplasms
Factor IX
Oncostatin M
Receptors, Oncostatin M

Reference

1. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007; 3. 245(3):366–378. PMID: 17435543.

2. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol. 2007; 2. 14(2):730–738. PMID: 17103065.

3. Arita K, South AP, Hans-Filho G, Sakuma TH, Lai-Cheong J, Clements S, et al. Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis. Am J Hum Genet. 2008; 1. 82(1):73–80. PMID: 18179886.

4. Isozaki O, Tsushima T, Miyakawa M, Emoto N, Demura H, Arai M, et al. Oncostatin M: a new potent inhibitor of iodine metabolism inhibits thyroid peroxidase gene expression but not DNA synthesis in porcine thyroid cells in culture. Thyroid. 1997; 2. 7(1):71–77. PMID: 9086575.

5. Klausen P, Pedersen L, Jurlander J, Baumann H. Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells. Oncogene. 2000; 7. 19(32):3675–3683. PMID: 10951574.

6. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003; 8. 374(Pt 1):1–20. PMID: 12773095.

7. Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol. 2003; 6. 149:39–52. PMID: 12811586.

8. Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmuller U, Nakajima K, et al. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene. 1999; 6. 18(25):3742–3753. PMID: 10391682.

9. Grant SL, Begley CG. The oncostatin M signalling pathway: reversing the neoplastic phenotype? Mol Med Today. 1999; 9. 5(9):406–412. PMID: 10462753.

10. Lacreusette A, Nguyen JM, Pandolfino MC, Khammari A, Dreno B, Jacques Y, et al. Loss of oncostatin M receptor [beta] in metastatic melanoma cells. Oncogene. 2006; 8. 26(6):881–892. PMID: 16909117.

11. Mori S, Murakami-Mori K, Bonavida B. Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor. Anticancer Res. 1999; Mar-Apr. 19(2A):1011–1015. PMID: 10368647.

12. Miles SA, Martinez-Maza O, Rezai A, Magpantay L, Kishimoto T, Nakamura S, et al. Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science. 1992; 3. 255(5050):1432–1434. PMID: 1542793.

13. Zhang XG, Gu JJ, Lu ZY, Yasukawa K, Yancopoulos GD, Turner K, et al. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med. 1994; 4. 179(4):1337–1342. PMID: 8145045.

14. Nishimoto N, Ogata A, Shima Y, Tani Y, Ogawa H, Nakagawa M, et al. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J Exp Med. 1994; 4. 179(4):1343–1347. PMID: 8145046.

15. Takamatsu J, Hosoya T, Tsuji M, Yamada M, Murakami Y, Sakane S, et al. Peroxidase and coupling activities of thyroid peroxidase in benign and malignant thyroid tumor tissues. Thyroid. 1992; 1. 2(3):193–196. PMID: 1422230.

16. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science. 2002; 6. 296(5576):2225–2229. PMID: 12029063.

17. Brown TJ, Lioubin MN, Marquardt H. Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes: synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. J Immunol. 1987; 11. 139(9):2977–2983. PMID: 3117884.

18. Liu J, Spence MJ, Wallace PM, Forcier K, Hellstrom I, Vestal RE. Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene. Cell Growth Differ. 1997; 6. 8(6):667–676. PMID: 9186000.

19. Deng G, Kakar S, Okudiara K, Choi E, Sleisenger MH, Kim YS. Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs. Clin Cancer Res. 2009; 3. 15(5):1519–1526. PMID: 19223499.

20. Halfter H, Lotfi R, Westermann R, Young P, Ringelstein EB, Stogbauer FT. Inhibition of growth and induction of differentiation of glioma cell lines by oncostatin M (OSM). Growth Factors. 1998; 3. 15(2):135–147. PMID: 9505169.

21. Kurebayashi J, Otsuki T, Tanaka K, Yamamoto Y, Moriya T, Sonoo H. Medroxyprogesterone acetate decreases secretion of interleukin-6 and parathyroid hormone-related protein in a new anaplastic thyroid cancer cell line, KTC-2. Thyroid. 2003; 3. 13(3):249–258. PMID: 12729473.

22. Lumachi F, Basso SM, Orlando R. Cytokines, thyroid diseases and thyroid cancer. Cytokine. 2010; 6. 50(3):229–233. PMID: 20381375.

23. Lee J, Rhee Y, Lee S, Ahn CW, Cha BS, Kim KR, et al. Frequent, aggressive behaviors of thyroid microcarcinomas in Korean patients. Endocr J. 2006; 10. 53(5):627–632. PMID: 16896263.

24. Sugino K, Ito K Jr, Ozaki O, Mimura T, Iwasaki H, Ito K. Papillary microcarcinoma of the thyroid. J Endocrinol Invest. 1998; Jul-Aug. 21(7):445–448. PMID: 9766259.

25. Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno-Bossio G, Caillou B, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer. 1998; 8. 83(3):553–559. PMID: 9690549.

26. Besic N, Pilko G, Petric R, Hocevar M, Zgajnar J. Papillary thyroid microcarcinoma: prognostic factors and treatment. J Surg Oncol. 2008; 3. 97(3):221–225. PMID: 18050283.

27. Antonaci A, Anello A, Aucello A, Consorti F, Della Rocca C, Giovannone G, et al. Microcarcinoma and incidental carcinoma of the thyroid in a clinical series: clinical behaviour and surgical management. Clin Ter. 2006; May-Jun. 157(3):225–229. PMID: 16900848.

28. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002; 8. 26(8):879–885. PMID: 12016468.